Study says CBD products sold are incorrectly labeled

A study conducted by Dr. Bonn-Miller from the Medical School of the University of Pennsylvania found out that two-thirds of CBD products online show incorrect data on cannabinoid content on their descriptions. Dr. Bonn-Miller's team purchased and tested 84 different online retail products labeled as "contains CBD." The products analyzed came from 31 different online vendors.

A study by Dr. Bonn-Milller of the Medical School of the University of Pennsylvania showed that up to two-thirds of products sold by online retailers show incorrect data on cannabinoid content in their descriptions.

Both in the US and in Europe are fragmented, mainly due to inconsistent legislation. Also, dozens of varying regulations within states and countries.

While most CBD products are not illegal, manufacturers often operate in a grey area. One of the practical consequences of this situation are the different qualities of CBD products.

The results of the study by Dr. Bonn-Miller’s team show, on the one hand, an obvious inaccuracy in the labeling of many CBD products. The Pennsylvania team purchased 84 different online retail products labeled “Contains CBD” from 31 different online vendors.

Triple tested

They test each product a total of three times, with the final results then averaged to the average value. And these were worrying – to put it mildly.

However, 26 percent showed the exact opposite. Only slightly more than 30 percent owned the approximate share of CBD stated on their labels. (Here a margin of 10 percent permits on the part of US pharmacology.)

Researchers found out that there’s inaccuracy when it comes to the CBD content of certain CBD products. (Source)

Interestingly, there were significant differences in the accuracy of the information on the respective labels regarding the product category. Meanwhile, fluids for vaporizers on their labels only achieved a truth content of 12.5 percent.

Especially in relation to vaporizer fluids, they hold the worst average of the content compared to the information on the label. Up to ten times the actual value could exceed or undercut the information.

A “very good” safety profile

According to Bonn-Miller’s results, fluctuations in the amount of CBD, a substance with a very good safety profile, are not dangerous, yet they lead the customer in the wrong direction. Finally, an overestimation of the actual content may prevent the purchaser from reaping the tangible benefits of the appropriate dose of CBD.

The conclusion of US research is universal in nature and concerns markets on both sides of the Atlantic. Closer monitoring of CBD products and prudent regulation on this issue appear essential.

The researchers point out that such a deviation. The actual and reported values to show that online merchants are exclusively for shopping. (These shops are usually a little more difficult to control so as not to have to call them obscure.) However, this is no excuse to grant orders online a different status.

Closer monitoring of CBD products and prudent regulation on this issue appear essential. (Source)

Certified and professional

Regardless of the efforts of regulatory bodies, the best guarantee for a verified quality in the composition of products is to focus on certified and professional distributors.

Each batch of CannabiGold, for example, is inspected by a multi-inspection that guarantees that the quantity stated on the packaging matches that of the product. And each vial is filled with the optimal composition of natural phytocannabinoids.

(Featured Image by Sabrina Rohwer)

First published in Hanf Journal a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.

Recent Posts

Ontario Increases Efforts to Combat Illegal Cannabis Market

Ontario is investing $31 million over the next three years to enhance efforts against illegal…

5 days ago

Hanover and Frankfurt Will Be the First German Cities to Legally Sell Cannabis for Adult Use

Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…

6 days ago

CBD Decree Suspended By Italian Administrative Court for Third Time

Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…

1 week ago

Which U.S. States Will Vote on Cannabis Legalization in November 2024?

This November, five U.S. states will vote on measures related to legalizing recreational or medical…

2 weeks ago

Italy to Be Investigated By EU Commission Over Proposed CBD and Hemp Ban

The European Commission has launched an investigation into Italy after its recent proposal to ban…

2 weeks ago

Prolonged Cannabis Use May Leave a Unique DNA Signatures

A new study has found that prolonged use of high-THC cannabis leaves a unique mark…

2 weeks ago